Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Allfunds Bank to acquire Nordic Fund Market
Mandate

Allfunds Bank to acquire Nordic Fund Market

March 29, 2019 M&A

Vinge has advised Allfunds Bank (“Allfunds”) in connection with entering into an agreement to acquire Nordic Fund Market ("NFM") from Nasdaq.

Allfunds is the leading institutional fund and wealthtech platform in Europe with more than €370 billion of AuA. NFM is an electronic mutual fund service that enables straight through processing of orders and settlements. The service enables the fund distributors to access a broad choice of mutual funds through one single interface. There are presently around 200 connected fund companies with more than 5,000 mutual funds available on the Nasdaq platform. Completion of the transaction is subject to customary conditions.

Vinge’s team consisted of, among others, Jonas Bergström and Carl Sander (M&A), Emma Stuart-Beck, Henrik Schön and Mikaela Lang (Financial Regulatory), Ulf Nilsson and Victor Ericsson (Tax), and Nicklas Thorgerzon (TSA/CA).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025